ClinicaliQ Trial Snapshot
- NAZA – Nottingham/Astra ZenecA Prospective IBD Cohort Study — Recruiting • Rheumatology • NCT06956703.
- What is being tested: This observational cohort study compares inflammatory markers between patients with inflammatory bowel disease (IBD) and non-IBD controls to identify potential biomarkers that distinguish IBD from other conditions.
- Patient eligibility overview: The study recruits both IBD patients (with confirmed diagnosis) and control participants without IBD, enabling direct comparison of inflammatory marker profiles between the two groups.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this observational study is to learn about the comparisons of inflammatory markers between IBD and non-IBD (control) participants. The main question it aims to answer is: Are there differences in inflammatory markers between IBD and non-IBD (control) participants.
Eligibility Snapshot
- : 1. Provision of signed and dated, written informed consent before any study specific procedures AND 2a. Patients of at least 16 years of age with active Crohn's disease defined as: CRP > = 5 mg/L OR FCP > = 250 μg/g OR Visible ulcerations on ileocolonoscopy with a total SES-CD > = 7, or > = 4 if disease is confined to the terminal ileum OR visable active disease on cross-sectional imaging. Are switching to a new mechanism of action (MOA) onto anti-TNF therapy or ustekinumab or upadacitinib OR 2b. Patients of at least 16 years (no upper age limit) with active UC defined as: CRP > = 5 mg/L OR FCP > = 250 μg/g OR Mayo endoscopy subscore > = 2. Are switching to a new mechanism of action (MOA) onto either anti-TNFα therapy or vedolizumab OR 2c. Non-IBD participants who are attending for a lower GI colonoscopy at any participating site. On any hospital/ medical/ clinical screening list or any other appropriate list with no pathology found on examination.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.